Medicare delayed a plan to make insurance companies cover GLP-1 drugs Wegovy and Zepbound. Instead, Medicare will cover the ...

Experts warn popular GLP‑1 drugs may pose added risks for some patients, highlighting the need for medical supervision.

Eli Lilly stock skidded early Friday as Novo Nordisk's oral Wegovy continued to outpace Lilly's new weight-loss pill, ...

The BALANCE program was intended to cover weight-loss drugs for Medicaid beneficiaries, but is delayed. A new solution with ...

A simple outpatient procedure may provide a majority of people who discontinue popular weight-loss drugs a way to prevent ...

GLP-1 supplements for weight loss cost less than GLP-1 drugs, but do they work? Doctors and experts explain how much weight you can expect to lose.

Drugmakers continue to test weight-loss medicines against dummy pills and shots, even with a growing number of effective approved obesity drugs. This practice raises practical questions.

The US Government will now pick up the cost of weight loss drugs offered through the Medicare GLP-1 Bridge scheme until 31 ...

The FDA has approved the second GLP-1 pill for overweight and obesity. How does it compare to the Wegovy oral pill?

Eli Lilly (NYSE:LLY) shares fell about 4% on Friday after data indicated its obesity drug prescriptions were trailing those of rival Novo Nordisk. Eli Lilly's weekly prescriptions for Zepbound ...

Variants in GLP‑1 and GIP receptor genes partly determine weight loss and nausea risk on GLP‑1 drugs, signaling a shift from ...